<DOC>
	<DOCNO>NCT01702376</DOCNO>
	<brief_summary>This randomize , placebo-controlled , single , oral dose , four-way Williams crossover study design healthy male female subject . The study consist screen ( 28 day ) , treatment ( 1 day/dosing session ) follow-up ( 7 14 day ) period total duration study participation subject approximately 9 week . Each subject participate 4 dose session separate minimum 7-day washout period . All subject receive single dos retosiban 100 mg , ( treatment A ) retosiban 800 mg ( Treatment B ) , moxifloxacin 400 mg ( Treatment C ) placebo ( Treatment D ) one four treatment sequence ( ABDC , BCAD , CDBA , DACB ) follow Williams design Twelve-lead ECGs continuous Holter monitoring , clinical laboratory safety test , vital sign measurement , physical examination , adverse event report , pharmacokinetic sample collect throughout study . In study period , cardiac conduction measure use 24-hour continuous 12-lead Holter monitor morning Day 1 ( dose ) morning Day 2 .</brief_summary>
	<brief_title>This Study Will Investigate Effect Single Oral Doses Retosiban Cardiac Repolarization , With Moxifloxacin Positive Control Healthy Volunteers .</brief_title>
	<detailed_description />
	<mesh_term>Obstetric Labor , Premature</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Male female 18 45 year age inclusive , time signing inform consent A female subject eligible participate : childbearing potential agrees use contraception method time consent 48 hour post last dose ; Nonchildbearing potential define premenopausal female document tubal ligation hysterectomy ; postmenopausal define 12 month spontaneous amenorrhea . Females hormone replacement therapy ( HRT ) whose menopausal status doubt require use contraception method wish continue HRT study . Otherwise , must discontinue HRT allow confirmation postmenopausal status prior study enrollment . For form HRT , least 2 4 week elapse cessation therapy blood draw ; interval depend type dosage HRT . Following confirmation postmenopausal status , resume use HRT study without use contraceptive method . Healthy determine responsible experienced physician , base medical evaluation include medical history , physical examination , laboratory test cardiac monitoring . A subject clinical abnormality laboratory parameter outside reference range population study may include Investigator GlaxoSmithKline ( GSK ) Medical Monitor agree find unlikely introduce additional risk factor interfere study procedure . Body weight ( great equal ) &gt; =50 kg body mass index ( BMI ) within range 19 29.9 kg/m^2 Capable give write informed consent , include compliance requirement restriction list consent form No significant abnormality 12lead ECG screening , include follow specific requirement : ventricular rate &gt; =40 beat per minute , PR interval less equal ( &lt; = ) 210 miliseconds ( msec ) , Q wave less ( &lt; ) 30 msec , QRS interval &gt; =60 msec &lt; 120 msec ; waveform must enable QT interval clearly define ; QTcB QTcF interval must &lt; 450 msec ALT , alkaline phosphatase bilirubin &lt; =1.5xULN ( isolate bilirubin great ( &gt; ) 1.5x upper limit normal ( ULN ) acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen . A supine blood pressure persistently high 140/90 millimeter mercury ( mmHg ) . A supine mean heart rate outside range 40 90 beat per minute ( bpm ) . Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . A positive prestudy drug/alcohol screen . A positive test Human Immunodeficiency Virus ( HIV ) antibody . History regular alcohol consumption within 6 month study define : average weekly intake &gt; 14 drink male &gt; 7 drink female . One drink equivalent 12 g alcohol : 12 ounce ( 360 ml [ milliliter ] ) beer , 5 ounce ( 150 ml ) wine 1.5 ounce ( 45 ml ) 80 proof distil spirit . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Exposure four new chemical entity within 12 month prior first dose day . History sensitivity study medication , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . Where participation study would result donation blood blood product excess 500 ml within 56 day period . Pregnant female determine positive serum human chorionic gonadotropin ( hCG ) test screen prior dosing . Lactating female . Unwillingness inability follow procedure outline protocol . Urinary cotinine level indicative smoke history regular use tobacco nicotinecontaining product within 6 month prior screen . Unable refrain consumption red wine , seville orange , grapefruit grapefruit juice and/or pummelo , exotic citrus fruit , grapefruit hybrid fruit juices 7 day prior first dose study medication . History presence medically significant disease , disorder would introduce additional risk interfere study procedure outcome . In particular , family history QT prolongation , early sudden cardiac death early cardiovascular disease . Use prescription nonprescription drug , include vitamin , herbal dietary supplement 14 day screen followup visit unless opinion Investigator sponsor medication interfere study compromise subject safety . Serum calcium , magnesium potassium level outside reference range History sensitivity quinolone antibiotic component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>